MRD Revenue Growth
MRD revenue increased 52% year-over-year, driven by clinical and pharma sectors. Key milestones include a 17% increase in the Medicare gapfill rate for the clonoSEQ test and securing Medicare coverage for mantle cell lymphoma.
Improved Operating Spend and Cash Burn
Operating spend declined 11% year-over-year, and cash burn reduced by 38% in the first nine months compared to the previous year.
Pharma Business Revenue Surge
Pharma revenue grew by 73% year-over-year, including $5 million in regulatory milestone revenue, with significant momentum following the ODAC recommendation.
Sequencing Gross Margin Increase
Sequencing gross margin increased by 6 percentage points compared to the last quarter due to efficiencies in workflow, leading to reduced per sample cost.
Epic EMR Integration Success
Completed Epic integrations for 6 accounts, including MD Anderson, now live with 11 accounts, and have 9 more scheduled by year-end, representing about 20% of projected 2024 volume.
Guidance Updates and Financial Improvements
Raised lower end of MRD revenue guidance for the full year and reduced full-year operating expense and cash burn targets.